Mirati Therapeutics
$57.08
29
+$0.33+0.58% Friday 21:00
Statistics
Day High
57.18
Day Low
56.62
52W High
96.58
52W Low
27.3
Volume
1,025,085
Avg. Volume
1,403,005
Mkt Cap
4B
P/E Ratio
-4.7
Dividend Yield
-
Dividend
-
Upcoming
Earnings
26FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-3.55
-3.2
-2.84
-2.49
Expected EPS
-2.6
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MRTX. It's not an investment recommendation.
Analyst Ratings
58.42$Average Price Target
The highest estimate is $72.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
31%
Hold
69%
Sell
0%
About
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Show more...
CEO
Charles Baum
Employees
199
Country
US
ISIN
US60468T1051
WKN
000A1W1XV